Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 3Recurrence 2Prostatic Neoplasms 2Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasm Metastasis 1Mucopolysaccharidosis I 1Liposarcoma 1Hodgkin Disease 1Disease Progression 1Carcinoma in Situ 1Advanced Malignant Solid Tumors 1

Interventions

vorolanib 3neratinib 3dacomitinib 1Vinorelbine 1TAK-243 1Premedication 1Paclitaxel 1Clinical Trials, Phase II as Topic 1Capecitabine 11-(4-(4-(3-oxa-8-azabicyclo(3.2.1)octan-8-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Malignant Solid Tumors × Clinical Trials, Phase II as Topic × Clear all
NCT06464055 2025-02-10

A Study of GQ1010 in Subjects With Advanced Solid Tumors

GeneQuantum Healthcare (Suzhou) Co., Ltd.

Phase 1/2 Recruiting
260 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡